Financial PositionMetagenomi trades at a discount to cash (~$100M market cap vs. ~$300M cash), mitigating risk.
Gene Editing AdvancementsMGX highlighted a recent Nature Communication publication showcasing its work on ancestral state reconstruction and structural biology to enhance gene editing systems.
Hemophilia A ProgramMetagenomi reported 16-month data for its Hemophilia A program in non-human primates showing enhanced durability, which is particularly important given limitations of traditional episomal gene therapy approaches.